These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21396153)

  • 1. Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study.
    Vieta E; Pappadopulos E; Mandel FS; Lombardo I
    Int J Neuropsychopharmacol; 2011 Sep; 14(8):1017-27. PubMed ID: 21396153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.
    Vieta E; Ramey T; Keller D; English PA; Loebel AD; Miceli J
    J Psychopharmacol; 2010 Apr; 24(4):547-58. PubMed ID: 19074536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
    Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
    Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
    Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
    J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment.
    Harvey PD; Endicott JM; Loebel AD
    Bipolar Disord; 2008 Dec; 10(8):900-6. PubMed ID: 19594505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Vanderburg DG; Karayal ON; Kolluri S; Bachinsky M; Cavus I
    J Clin Psychiatry; 2012 Nov; 73(11):1412-9. PubMed ID: 23218157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
    Sachs GS; Grossman F; Ghaemi SN; Okamoto A; Bowden CL
    Am J Psychiatry; 2002 Jul; 159(7):1146-54. PubMed ID: 12091192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
    Potkin SG; Weiden PJ; Loebel AD; Warrington LE; Watsky EJ; Siu CO
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies.
    Stahl S; Lombardo I; Loebel A; Mandel FS
    J Affect Disord; 2010 Apr; 122(1-2):39-45. PubMed ID: 19616304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
    Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
    J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.
    Citrome L; Yang R; Glue P; Karayal ON
    Schizophr Res; 2009 Jun; 111(1-3):39-45. PubMed ID: 19375893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 2: influence of protocol-specific eligibility criteria on signal detection.
    Sachs GS; Vanderburg DG; Edman S; Karayal ON; Kolluri S; Bachinsky M; Cavus I
    J Clin Psychiatry; 2012 Nov; 73(11):1420-5. PubMed ID: 23218158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ziprasidone and mania.
    Ross DE
    Am J Psychiatry; 2004 Aug; 161(8):1503. PubMed ID: 15285991
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
    J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Young mania rating scale line item analysis in pediatric subjects with bipolar I disorder treated with aripiprazole in a short-term, double-blind, randomized study.
    Mankoski R; Zhao J; Carson WH; Mathew SJ; Forbes RA
    J Child Adolesc Psychopharmacol; 2011 Aug; 21(4):359-64. PubMed ID: 21823911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales.
    Widschwendter CG; Karayal ON; Kolluri S; Vanderburg D; Kemmler G; Fleischhacker WW
    Int J Neuropsychopharmacol; 2015 Jun; 18(12):. PubMed ID: 26116494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.
    Suppes T; McElroy SL; Sheehan DV; Hidalgo RB; Cosgrove VE; Gwizdowski IS; Feldman NS
    J Clin Psychiatry; 2014 Jan; 75(1):77-84. PubMed ID: 24345758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
    Ketter TA; Agid O; Kapur S; Loebel A; Siu CO; Romano SJ
    J Psychiatr Res; 2010 Jan; 44(1):8-14. PubMed ID: 19699488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.